Nottingham Advisors Inc. Sells 87,938 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Nottingham Advisors Inc. lowered its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 47.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 97,828 shares of the biopharmaceutical company’s stock after selling 87,938 shares during the quarter. Nottingham Advisors Inc.’s holdings in Ocular Therapeutix were worth $835,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP lifted its holdings in shares of Ocular Therapeutix by 1.0% during the 4th quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company’s stock worth $3,991,000 after acquiring an additional 4,488 shares during the period. JPMorgan Chase & Co. raised its position in Ocular Therapeutix by 123.6% in the fourth quarter. JPMorgan Chase & Co. now owns 189,295 shares of the biopharmaceutical company’s stock worth $1,617,000 after purchasing an additional 104,650 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in Ocular Therapeutix by 26.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company’s stock worth $11,398,000 after purchasing an additional 278,610 shares during the period. Vanguard Group Inc. boosted its holdings in Ocular Therapeutix by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company’s stock valued at $72,453,000 after purchasing an additional 99,730 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Ocular Therapeutix in the 4th quarter valued at approximately $149,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock opened at $7.34 on Thursday. The stock has a 50-day simple moving average of $7.47 and a 200 day simple moving average of $8.72. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -5.56 and a beta of 1.49. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 12-month low of $4.06 and a 12-month high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. On average, research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on OCUL. JMP Securities set a $19.00 price target on Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, Needham & Company LLC began coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 11th. They issued a “buy” rating and a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.38.

Insider Buying and Selling

In other news, insider Donald Notman sold 11,119 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the sale, the insider now owns 193,444 shares in the company, valued at $1,510,797.64. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock worth $283,772 in the last quarter. Insiders own 3.50% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.